Anand Rathi has maintained a 'Buy' rating on Max Healthcare, setting a target of Rs 1,220, following a robust Q1 FY27 performance. While the company is actively expanding through new hospital beds and strategic acquisitions, investors are also monitoring the rise in net debt and temporary pressure on profit margins.
Anand Rathi has maintained a 'Buy' rating on Max Healthcare Institute Limited, setting a target price of Rs 1,220. The brokerage’s outlook follows the hospital chain's recent Q1 FY27 financial results, which showed steady growth in operations even as the company pursues an aggressive expansion strategy.
Max Healthcare reported a gross revenue of Rs 2,982 crore for the April-June quarter, a 16% increase compared to the same period last year. Operating profit, or EBITDA, also grew by 15% to reach Rs 704 crore. Despite this growth, the company saw some pressure on its profit margins, which stood at 24.8%. This dip is primarily attributed to the costs associated with integrating new assets and the expenses from newly opened hospital capacity.
The company is currently in a phase of rapid growth. The board has cleared an investment of Rs 425 crore to build a new 202-bed tower at the existing MSSH facility in Vaishali. This follows recent inorganic growth steps, including the acquisition of a 58.28% stake in Kalinga Hospital and the full acquisition of Yerawada Properties, which is earmarked for a 450-bed hospital project in Pune. By the end of June 2026, the company’s total operational bed capacity had reached 5,379, representing an addition of 630 beds over the previous year.
Beyond hospital services, Max Healthcare is moving into the medical education sector, having received initial approval for this new business line. This is part of a broader attempt to diversify revenue sources.
While growth is a priority, investors should also note the recent shift in the company's financial position. Net debt increased to Rs 2,384 crore as of June 2026, up from Rs 1,908 crore in March 2026, largely due to spending on these acquisitions and new projects. Additionally, the company has faced temporary headwinds in its oncology business due to the discontinuation of certain chemotherapy drugs. The company expects this to normalize by the second half of the year.
For investors, the key monitorables will be how quickly the company can integrate these new facilities and improve margins as the new capacity begins to function at higher levels. Tracking the progress of the Vaishali expansion and the Pune project will be important to understand the company's future cash flow and debt management.